CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Returned to the company · Stock Option (right to buy) | −25,000 | 0 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Returned to the company · Stock Option (right to buy) | −106,000 | 0 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +106,000 | 106,000 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +925,000 | 925,000 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −155,090 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | −155,090 | 155,090 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −23,786 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +23,786 | 23,786 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −37,296 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +37,296 | 37,296 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −45,000 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −20,000 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −117,000 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +117,000 | 117,000 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −150,000 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 |
Page 3 of 12 · 224 trades